The Relationship between Types of Bone Cell Death, Clinical Characteristics, and Radiographic Findings in Medication-Related Osteonecrosis of the Jaw Patients

• Conditions: Medication-Related Osteonecrosis of the Jaw; Osteonecrosis; Bisphosphonates; Denosumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Death

• Registration Number: TCTR20230317001
• Lead Sponsor: Faculty of Dentistry, Chiang Mai University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-17
• Last Update Posted: 19 August 2024
• Study Completion: 2026-02-28

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Patients are 25 years old or over.
2. Patients with a history of receiving bisphosphonate or denosumab who have been diagnosed with MRONJ. (for MRONJ patients)
3. Patients with bony sequestrum who are undergoing sequestrectomy surgical procedures. (for MRONJ patients)
4. Patients with mandibular tori, palatal tori, or alveolar bone exsostosis who are undergoing torectomy or alveoloplasty surgical procedures. (for Healthy patients)

Exclusion Criteria

1. Patients with a history of health conditions or receiving other medication that affects the bone remodeling process such as uncontrol Diabetes Mellitus patients, or steroid-receiving patients.
2. Patients with a history of metastatic cancer in the oral and maxillofacial region.
3. Patients with a history of head and neck radiation therapy.
4. Heavy smoking patients.
5. Alcoholic patients.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Dominant pathway of cell death at 6 months after surgery. qRT-PCR and Western blotting

Secondary Outcome Measures

Name	Time	Method
Clinical characteristics at 6 months after surgery. Examination,Radiographical characteristics at 6 months after surgery. Radiographical examination (orthopantomography)